Table 1 Clinical characteristics of the patients are shown in three groups; all, patients with kidney function worsened or not at the end of the follow-up

Age, mean ± SD

68.7 ± 10.4

67 ± 9

69 ± 11

0.300

Male sex

57 (60)

12 (50)

45 (63.3)

0.675

Diabetes mellitus

40 (42.1)

15 (62.5)

25 (35.2)

0.019

Hypertension

81 (85.3)

21 (87.5)

60 (84.5)

0.506

CKD

71 (74.7)

18 (75)

53 (74.6)

0.973

Ischemic heart disease

40 (42.1)

12 (50)

28 (39.4)

0.365

Peripheral vascular disease

13 (13.7)

5 (20.8)

8 (11.2)

0.238

The number of anti-hypertensives

3 (2–4)

3 (2–5)

3 (2–4)

0.074

Normal

5 (5.3)

None

5 (7)

N/A

Elevated

22 (23.2)

8 (33.3)

14 (19.7)

Hypertension

50 (52.6)

9 (37.6)

41 (57.7)

Resistant HT

18 (18.9)

7 (29.1)

11 (15.4)

Systolic BP, mm Hg

164 ± 32

176 ± 31

160 ± 31

0.042

Diastolic BP, mm Hg

88 ± 19

93 ± 17

86 ± 19

0.037

Pulse pressure, mm Hg

76 ± 22

82 ± 20

73 ± 22

0.096

SCr, mg/dL, median (IQR)

1.57 (1.11–2.12)

1.50 (1.04–2.74)

1.58 (1.09–1.97)

0.024

eGFR, ml/min, median (IQR)

40 (27–58)

43 (19–59)

39 (28–58)

0.056

Triglyceride, mg/dL median (IQR)

139 (98–210)

178 (118–263)

131 (91–202)

0.050

LDL-cholesterol, mg/dL, median (IQR)

122 (98–149)

123 (90–149)

122 (99–149)

0.746

Serum uric acid, mg/dL

7.0 (6.0-8.8)

6.9 (5.3–8.2)

7.0 (6.0–9.0)

0.238

C-reactive protein, mg/L

4.9 (2.0-8.8)

4.3 (2.5–7.1)

5 (1.9–9.5)

0.903

Unilateral

67 (70)

20 (83.3)

47 (66.1)

0.111

Bilateral

28 (30)

4 (16.6)

24 (33.8)

Peak systolic velocity, cm/sec median (IQR)

300 (300–400)

350 (280–400)

300 (300–400)

0.504

Resistive index

0.67 (0.58–0.75)

0.72 (0.65–0.75)

0.65 (0.57–0.75)

0.149